.2 mg glp 1 GLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, EMA Warns Investigational Dual GLP-1/GIP Agonist CT-388

Aide la perte de poids Un regroupement de huit mta-analyses (16 352 participants) conclut une perte moyenne de 1,1 kg et une diminution significative du tour de taille aprs 830 semaines de 150 4 000 mg/j

2025;17(9):e70151

Patients whose first prescription came from an endocrinologist were 10% less likely to stop treatment

Heres what makes it attractive: Predictable Bioavailability When you inject Selank subcutaneously or intramuscularly, you know exactly how much is getting into the system

466 One study proposed a novel mechanism wherein postprandial GLP-1 release, under normal physiological conditions, inhibits the activity of chemosensory cells in the carotid body, thereby counteracting sympathetic excitability mediated by elevated blood glucose or insulin levels